Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RPRX

+ Watchlist+ Portfolio

Royalty Pharma plc

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$68.68
52-Week Range
$37.31 – $70.37
Market Cap
$39.48B
P/E (TTM)
44.88
EPS (TTM)
1.53
Dividend Yield
1.37%
Advanced Metrics
Price/Book
4.48
PEG Ratio
2.08
Return on Equity
12.09%
Return on Assets
5.43%
Gross Margin
99.79%
Operating Margin
64.41%
Profit Margin
25.70%
Current Ratio
1.29
Debt/Equity
0.88
Total Debt
$8.59B
Free Cash Flow
$-450.27M
Revenue Growth
13.30%
Earnings Growth
-50.80%
Enterprise Value
$41.58B

Market Snapshot

About

Royalty Pharma is the largest buyer of biopharmaceutical royalties, owning royalty interests in dozens of commercial and development-stage products. The company acquires royalty streams from pharmaceutical companies and academic institutions, providing upfront capital in exchange for future revenue shares. Royalty Pharma's portfolio includes treatments across therapeutic areas including immunology, infectious disease, oncology, and rare diseases. The firm operates a diversified revenue model based on the commercial success of approved therapies.